Research programme: anti-inflammatory therapeutics - Amagma Therapeutics
Alternative Names: Research programme: anti-inflammatory antibodies- Amagma Therapeutics; Research programme: anti-inflammatory enzyme inhibitors - Amagma TherapeuticsLatest Information Update: 02 Feb 2022
At a glance
- Originator Amagma Therapeutics
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 02 Feb 2022 Amagma Therapeutics plans to file IND applications for Inflammation (Second line therapy, Late stage disease) in the second quarter of 2024 (Amagma Therapeutics pipeline, February 2022)
- 02 Feb 2022 Amagma Therapeutics plans to file an IND application for Inflammation in the third quarter of 2023 (Amagma Therapeutics pipeline, February 2022)
- 18 Jan 2022 Amagma Therapeutics enters a license option agreement with Innovent Biologics for developing anti-inflammatory therapeutics